Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

(2013) Hyungshin Yim   ANTI-CANCER DRUGS

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

(2013) Walter M. Stadler et al.   CANCER

Acute myeloid leukaemia in adults

(2013) Felicetto Ferrara et al.   LANCET

ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress

(2012) C. M. Chapman et al.   CLINICAL CANCER RESEARCH

Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid Leukemia

(2012) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

(2012) B. Valsasina et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

(2011) D. Olmos et al.   CLINICAL CANCER RESEARCH

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies

(2011) Daniel C Christoph et al.   Expert Review of Anticancer Therapy

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

(2011) Y. Hikichi et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

AML in older patients: Are we making progress?

(2009) Elihu Estey   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia

(2008) Christine Didier et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY